Target
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
4 abstracts
Abstract
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.Org: Greenwich LifeSciences, Stafford, TX, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine,
Abstract
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.Org: Greenwich LifeSciences, Stafford, TX, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine,
Abstract
Effect of multi-targeting bacterial gene therapy on tumour regression and survival in mouse models of ovarian and intraperitoneal cancer.Org: Aurealis Therapeutics, Kuopio University Hospital, Finland, Basel, Switzerland, Switzerland,
Abstract
Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).Org: Targovax ASA, Hospital Universitari Vall d´Hebron and Vall d´Hebron Institute of Oncology (VHIO), CHU Rennes – Hôpital Pontchaillou, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit,